We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy Intervenes in Mylan Generic Diovan Suit Against FDA
Ranbaxy Intervenes in Mylan Generic Diovan Suit Against FDA
October 23, 2012
Ranbaxy has been granted the right to intervene as a defendant in a lawsuit that could determine whether Ranbaxy or its generic competitor Mylan will get 180-day exclusivity for generic versions of Novartis’ Diovan.